FDA awards GSA breakthrough status for relapsed osteosarcoma treatment

GSK has gained US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for its B7-H3-targeted antibody-drug conjugate (ADC), GSK'227, to treat adults with relapsed or refractory … [+2396 chars]